EcoDrugPlus

Dihydropyrimidine Dehydrogenase

Ensembl ID : ENSLLEG00000026742
Gene Symbol: DPYD
1 View Cross-references
224 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Discoidin Domain Receptor Tyrosine Kinase 2

Ensembl ID : ENSLLEG00000027059
Gene Symbol: DDR2
1 View Cross-references
265 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Dopamine Receptor D1

Ensembl ID : ENSLLEG00000006740
Gene Symbol: DRD1
1 View Cross-references
261 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Dopamine Receptor D2

Ensembl ID : ENSLLEG00000016212
Gene Symbol: DRD2
1 View Cross-references
219 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Dopamine Receptor D4

Ensembl ID : ENSLLEG00000013523
Gene Symbol: DRD4
1 View Cross-references
246 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Dopamine Receptor D5

Ensembl ID : ENSLLEG00000002175
Gene Symbol: DRD5
1 View Cross-references
186 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Ectonucleotide Pyrophosphatase/phosphodiesterase 2

Ensembl ID : ENSLLEG00000008761
Gene Symbol: ENPP2
1 View Cross-references
227 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Egl-9 Family Hypoxia Inducible Factor 1

Ensembl ID : ENSLLEG00000009815
Gene Symbol: EGLN1
1 View Cross-references
235 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Egl-9 Family Hypoxia Inducible Factor 2

Ensembl ID : ENSLLEG00000030964
Gene Symbol: EGLN2
1 View Cross-references
197 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Egl-9 Family Hypoxia Inducible Factor 3

Ensembl ID : ENSLLEG00000009621
Gene Symbol: EGLN3
1 View Cross-references
209 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Endothelial Pas Domain Protein 1

Ensembl ID : ENSLLEG00000008398
Gene Symbol: EPAS1
1 View Cross-references
222 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Endothelin Converting Enzyme 1

Ensembl ID : ENSLLEG00000020073
Gene Symbol: ECE1
1 View Cross-references
230 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).